CD95 (APO-1/Fas) Monoclonal Antibody (EOS9.1), Functional Grade, eBioscience™, Invitrogen™

Description

Description: The EOS9.1 monoclonal antibody reacts with human CD95 (Fas, Apo-1), a 40-50 kDa member of the TNFR superfamily. CD95 is expressed by a broad range of hematopoietic and non-hematopoietic cells including monocytes, neutrophils, activated lymphocytes and fibroblasts. Interaction of CD95 on mature lymphocytes with its ligand (FasL) induces apoptosis and is thought to be important in peripheral tolerance. EOS9.1 does not block binding of DX2, another antibody specific for human CD95. Applications Reported: The EOS9.1 antibody has been reported for use in flow cytometric analysis. EOS9.1 is also effective in inducing apoptosis in in vitro functional studies. Applications Tested: The EOS9.1 antibody has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Storage and handling: Use in a sterile environment. Filtration: 0.2 μm post-manufacturing filtered. Purity: Greater than 90%, as determined by SDS-PAGE. Endotoxin Level: Less than 0.001 ng/μg antibody, as determined by LAL assay. Aggregation: Less than 10%, as determined by HPLC.

FAS (Fas, CD95, APO-1) is a 46 kDa transmembrane glycoprotein that functions as a cell death receptor of the TNFR (tumor necrosis factor receptor) superfamily. FAS also exists in a soluble form that weight approximately 26kDa. Stimulation of FAS results in aggregation of its intracellular FAS-associated death domains (FADD), formation of the death-inducing signaling complex (DISC) and activation of caspases. The auto-proteolytic processing of the caspases in the complex trigger a downstream cascade that leads to apoptosis. FAS has been shown to activate NF-kappaB, MAPK3/ERK1, MAPK8/JNK, and is involved in transducing the proliferating signals in normal diploid fibroblast and T cells. At least eight alternatively spliced transcript variants encoding seven distinct isoforms have been described. The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full-length isoform. The Fas/Fas ligand system has been shown to play a role in a number of human diseases such as AIDS, hepatitis and cancer. It is also assumed that induction of apoptosis through FAS ligand pathway is predominantly involved in anti-viral immune responses.